Back to Search
ANDREW LIPTON, MD
MD
Pediatric Pulmonology Physician
NPI: 1245278308Individual
Specialties, Licenses & Credentials
Pediatric Pulmonology PhysicianPrimary
Pediatrics — Pediatric Pulmonology
Code: 2080P0214X
DR.0066248(CO)
Research & Publications (20)
Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure.
PMID 19653815·J Bone Miner Res·2010
3-trial
Phase I trial of zoledronic acid + imatinib mesylate (Gleevec) in patients with bone metastases.
PMID 19652577·Am J Clin Oncol·2010
3-trial
Elevated plasma endoglin (CD105) predicts decreased response and survival in a metastatic breast cancer trial of hormone therapy.
PMID 19115106·Breast Cancer Res Treat·2010
3-trial
Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity.
PMID 19660124·BMC Cancer·2009
2-rct
Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.
PMID 19237632·J Clin Oncol·2009
3-trial
Magnesium silicate dissolution investigated by 29Si MAS, 1H-29Si CPMAS, 25Mg QCPMG, and 1H-25Mg CP QCPMG NMR.
PMID 19652836·Phys Chem Chem Phys·2009
8-other
RANKL inhibition in the treatment of bone metastases.
PMID 18685421·Curr Opin Support Palliat Care·2008
6-review
Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions.
PMID 18579314·Cancer Treat Rev·2008
6-review
Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor.
PMID 18757423·Cancer Res·2008
7-preclinical
Emerging role of bisphosphonates in the clinic--antitumor activity and prevention of metastasis to bone.
PMID 18486347·Cancer Treat Rev·2008
6-review
Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid.
PMID 18459173·Cancer·2008
8-other
Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database.
PMID 18720527·Cancer·2008
8-other
Characterization of Mg2+ binding to the DNA repair protein apurinic/apyrimidic endonuclease 1 via solid-state 25Mg NMR spectroscopy.
PMID 18576638·J Am Chem Soc·2008
8-other
Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference.
PMID 18927277·Clin Cancer Res·2008
6-review
Residue ionization in LpxC directly observed by 67Zn NMR spectroscopy.
PMID 18761443·J Am Chem Soc·2008
8-other
67Zn solid-state NMR spectroscopy of ([Tp But,Me]Zn(OH2))[HOB(C6F5)3]. the importance of the anion [HOB(C6F5)3]-.
PMID 18470984·Inorg Chem·2008
8-other
Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies.
PMID 18486346·Cancer Treat Rev·2008
6-review
Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer.
PMID 18661530·Cancer·2008
4-observational
Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy.
PMID 18927312·Clin Cancer Res·2008
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 10 CENTER DR MSC 1473 BDG 10-CRC RM 5-1408
BETHESDA, MD 20889 - Phone
- (301) 451-4950
Quick Facts
- NPI
- 1245278308
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile